Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chymopapain--past and present, future?

L T Ford

    Clinical Orthopaedics and Related Research
    |January 1, 1977
    PubMed
    Summary
    This summary is machine-generated.

    Clinical experience with Chymopapain suggests it is effective for lumbar disc disease, potentially reducing surgery rates. However, doubts arise from limited studies conducted by inexperienced surgeons.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Experimental evaluation of chymopapain in cats.

    Orthopedics·2014
    Same author

    Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment; a pharmacogenomic test whose time has come.

    Journal of clinical pathology·2010
    Same author

    Sequence comparisons of ruminant renal Na+/phosphate co-transporters.

    Biochemical Society transactions·1998
    Same author

    Towards molecular characterisation of ovine renal Na+/phosphate co-transporter; a progress report.

    Biochemical Society transactions·1997
    Same author

    Adult diastematomyelia.

    Spine·1994
    Same author

    An update on chymopapain for treating lumbar disc ruptures.

    Missouri medicine·1990

    Area of Science:

    • Neurosurgery
    • Pharmacology

    Background:

    • Chymopapain is an enzyme used for treating lumbar disc disease.
    • Limited double-blind studies have reported on its efficacy, primarily conducted by surgeons with varying experience levels in disc injection techniques.

    Observation:

    • Clinical experience with Chymopapain contrasts with the results from existing double-blind studies.
    • Surgeons and residents performing the disc injection technique may lack sufficient experience, influencing study outcomes.

    Findings:

    • Chymopapain, when administered correctly, is a valuable therapeutic agent for lumbar disc disease.
    • The drug demonstrates potential to significantly decrease the need for lumbar disc surgery, possibly by up to 75%.

    Implications:

    Related Experiment Videos

  • Chymopapain's efficacy warrants further investigation and broader clinical application.
  • Regulatory approval, such as a Phase IV basis by the FDA, could facilitate wider access and validation.
  • Availability in Canada and England contrasts with its absence in the U.S., highlighting international regulatory differences.